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INTRODUCTION
Myelodysplastic syndrome (MDS) refers to a heterogenous
group of acquired bone marrow disorders that is character-
ized by dysplastic growth of the hematopoietic progenitors,
a hypercellular bone marrow with peripheral cytopenia and
a propensity for these disease to progress onward to acute
leukemia (1). The overproduction of the proapoptotic cyto-
kines such as tumor necrosis factor-alpha (TNF- ), soluble
Fas ligand, MIP-1 , TGF- , IL-1 , IL-6 and interferon-
gamma (IFN- ) has been demonstrated in the bone marrow
microenvironment and in the plasma of the patients with
MDS, and this may contribute to the excessive apoptotic cell
death observed in MDS (2, 3). TNF- is a pleotropic immu-
nomodulatory cytokine and a potent inhibitor of hemato-
poiesis; in vitro, TNF- suppresses colony formation and
the proliferation of normal hematopoietic progenitor cells
and the malignant hematopoietic cell lines (4-7). Further,
neutralization of TNF- enhances the outgrowth of the
hematopoietic progenitor cells in MDS (8). Elevation of the
plasma TNF- level correlates with oxidative DNA injury
and depletion of cellular glutathione in CD34+ cells, as well
as caspase-3 activity (9, 10). These findings support an effec-
tor or potentiating role for these cytokines in the ineffective
hematopoiesis of MDS.
Pentoxifylline is known to interfere with the lipid-signaling
pathway used by TNF- , TGF- and IL-1 , and it reduces
the activity of these cytokines. Ciprofloxacin is known to reduce
the hepatic metabolism of pentoxifylline and dexametasone,
and it down-regulates the translation of the mRNA for TNF-
(11, 12).
Pentoxifylline, ciprofloxacine and dexamethasone (PCD)
therapy induced positive hematologic responses in 18 of 43
patients with MDS. The mechanism of action was found to
be cytokine related by the the fact that the responders showed
a sustained reduction of their TNF- levels (12). The pur-
pose of this study was to verify the response rate and the tox-
icity profile for the PCD therapy that was observed in the
first study by Raza (12).
MATERIALS AND METHODS
Patients
From April 2002 to December 2003, 17 female patients
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The Hematologic Response to Anti-apoptotic Cytokine Therapy: Results
of Pentoxifylline, Ciprofloxacin, and Dexamethasone Treatment for
Patients with Myelodysplastic Syndrome
TNF- mediated apoptosis of the hematopoietic cells has been thought to contribute
to the ineffective hematopoiesis observed in myelodysplastic syndrome (MDS). The
combination of pentoxifylline (P) and ciprofloxacin (C) has been shown to reduce
the serum levels of TNF- , and an earlier trial of P and C with dexamethasone (D)
provided good palliation for patients with MDS. The purpose of this study is to assess
the hematologic response to PCD therapy for patients suffering with MDS. 21 of
25 patients who completed at least of 12 weeks of treatment were evaluable for
the treatment efficacy. At baseline, the patient’s median age was 60 yr (range: 18-
75 yr). The diagnoses according to WHO classification included: RA (n=5), RCMD
(n=10), RARS (n=1), RCMD/RS (n=1), RAEB (3), and CMML (n=1). 11 patients
(52%) had at least single lineage response. 3 patients (11%) showed improvement
of triple lineage cytopenia. There were no differences in the response rates between
the FAB subtypes. The median time to response was 4 weeks (range: 2-12 weeks),
and it is interesting that 9 of 11 patients who had a response remained without relapse
for a median of 177 days (range: 78-634 days). These preliminary results indicate
that anti-cytokine therapy with PCD is an effective and well tolerated palliative treat-
ment for patients with MDS. 
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and 8 male patients with untreated MDS were enrolled in
this study. The diagnosis of MDS was established based on
the characteristic morphological abnormalities in the bone
marrow and/or by the presence of cytogenetic abnormalities
and peripheral cytopenia: all the patients were subclassified
according to both the French-American-British (FAB) nomen-
clature and the WHO classification scheme (13-15). The
study protocol was reviewed and approved by the Institutional
Review Boards of the Yeungnam University Medical Center
and Daegu Catholic University Hospital. All the patients
provided us with a written informed consent.
Twenty-one of 25 patients completed at least 12 weeks of
treatment, and so 21 patients are finally evaluable for the
treatment efficacy.
Treatment
The patients were treated with 1,200 mg of pentoxifylline
(P) that was divided into three doses per day, 500 mg of cip-
rofloxacin (C) that was divided into two doses per day, and
4 mg of dexamethasone (D) that was divided into two daily
doses, and this combined treatment was given for 4 weeks.
After this 4-week course, P 800 mg and C 500 mg were
given 3 times a week with 4 mg of D being given for 5 days
every month for 2 months. The therapy was stopped for the
nonresponding patients at this time and they were taken off
the study. The protocol called for continuing all the drugs
for 1 yr for the responders if the side effects were tolerable
and the responses were persistently observed.
Response evaluation and its criteria
The complete blood counts with differentials were obtained
every week for all the patients. The hematologic response was
evaluated using the International Working Group criteria (16).
The erythroid response (HI-E) was classified as follows: a
major response was defined for those patients with a pretreat-
ment hemoglobin level less than 11 g/dL as greater than a 2
g/dL increase in their hemoglobin level; for the RBC trans-
fusion-dependent patients, a major response was independence
from RBC transfusions. A minor response was defined for
those patients with a pretreatment hemoglobin level less than
11 g/dL as a 1 to 2 g/dL increase in their hemoglobin level;
for the RBC transfusion-dependent patients, a major response
was a 50% decrease in the transfusion requirement.
The platelet response (HI-P) was identified as follows: a
major response for patients with a pretreatment platelet count
of less than 100,000/ L was defined as an absolute increase
of 30,000/ L or more; for the platelet transfusion-dependent
patients, a major response was defined as stabilization of the
platelet counts and independence from platelet transfusion.
A minor response was defined for patients with a pretreat-
ment platelet count of less than 100,000/ L as a 50% or
more increase in the platelet count with a net increase greater
than 10,000/ L, but less than 30,000/ L.
The neutrophil response (HI-N) was classified as follows:
a major response was defined for the patients with an absolute
neutrophil count (ANC) less than 1,500/ L before therapy
as at least a 100% increase or an absolute increase of more
than 500/ L. A minor response was defined for patients with
an ANC less than 1,500/ L before therapy as an ANC increase
of at least 100%, but an absolute increase less than 500/ L.
To be considered as a major or minor improvement, the
hematologic improvements must have lasted for at least 2
months in the absence of ongoing cytotoxic therapy.
Cytogenetic studies
Karyotypic analysis using GTG banding was initially per-
formed for every patient by using unstimulated 24 hr cultures
and/or methotrexate-thymidine synchronized cultures.
Statistical analysis
Paired t-tests were used for 2 sample comparisons of the
continuous variables. The comparisons of the categorical vari-
*Good, normal, -Y, del(5q), del(20q); Poor, complex (≥3 abnormalities)
or chromosome 7 abnormalities; Intermediate, other abnormalities.
RA, refractory anemia; RCMD, refractory cytopenia with multilineage
dysplasia; RARS, refractory anemia with ringed sideroblasts; RCMD-
RS, refractory cytopenia with multilineage dysplasia with ringed sider-
oblasts; CMML, chronic myelomonocytic leukemia; MDS/MPD, myelodys-
plastic/myeloproliperative disease; IPSS, international prognostic scor-
ing system; ANC, absolute neutrophil count.
Median age, yr (range) 60 (18-75)
Gender, n (%)
Male 7 (33%)
Female 14 (67%)
FAB/WHO classification
RA RA 5 (24%)
RCMD 10 (48%)
RARS RARS 1 (5%)
RCMD/RS 1 (5%)
RAEB RAEB-I/II 1/2 (14%)
CMML MDS/MPD 1 (5%)
IPSS
Low 1 (5%)
Intermediate-1 16 (76%)
Intermediate-2 2 (10%)
High 2 (10%)
Karyotype*
Good 12 (57%)
Intermediate 8 (38%)
Poor 1 (5%)
Disease duration (months) 17.9±38.2
ANC counts (×10
9/L) 1.22±0.65
Hemoglobin levels (g/dL) 7.5±1.6
Platelet counts (×10
9/L) 79.3±88.7
Table 1. The patients’ demographics and baseline characteris-
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ables were performed by using  2-tests or Fisher’s exact tests
as appropriate. All the tests were two-sided and the p-values
less than 5% were considered statistically significant. The
analyses were performed using SPSS for Windows version
12.0 (SPSS Inc., Chicago, IL, U.S.A.).
RESULTS
Patient and disease characteristics
Of the 25 patients enrolled in this study, 1 patient died of
sepsis immediately after registration to this study, and 1
other patient was registered, but that patient could not keep
taking the medication due to a concomitant herniated cervi-
cal disc that required an operation. Of the 23 patients who
were evaluable for toxicity, 2 patients prematurely stopped
their therapy because of intolerable nausea and epigastric
sores, respectively.
Twenty-one patients completed at least a 12-week course
of therapy and so they were evaluable for a response to treat-
ment. The patients’ demographics and baseline disease char-
acteristics are summarized in Table 1.
Hematologic improvement
The hematologic improvement (HI) is summarized in Table
2 and the individual patient data and their baseline charac-
teristics are listed in Table 3. The median time to response
varied depending upon the nature of the response: the median
time to response was 4 weeks for HI-E (range; 2-8 weeks), 6
weeks for HI-P (range; 2-8 weeks), and 3 weeks for HI-N
(range; 2-16 weeks). Fig. 1, 2, and 3 depicts the serial hemo-
globin levels, the RBC requirements, the platelet counts and
the neutrophil counts for the responding patients. With the
exception of the patient 8, whose disease progressed on to acute
myelogenous leukemia at 8.2 months after PCD therapy,
the other 10 responding patients were still responding at the
time of analysis. Therefore the median duration of response
was not reached with a range of 3.6-20.9 months.
Response No. of patients (%)
Any response 11 (52%)
No response 10 (48%)
Erythroid response 7 (33%)
Major 4 (19%)
Minor 3 (14%)
No response 14 (67%)
Platelet response 5 (24%)
Major 3 (14%)
Minor 2 (10%)
No response 16 (76%)
Neutrophil response 6 (29%)
Major 6 (29%)
Minor 0 (0%)
No response 15 (71%)
Table 2. Hematologic improvement (HI) to the PCD treatment
Patient Age (yr) FAB/WHO IPSS
Baseline
ANC (×10
9/L) Hb (g/dL) Plt (×10
9/L)
Hematologic improvement Sex
1 64 M CMML INT-1 1.66 7.0 415 HI-E,major
2 19 F RA/RCMD INT-1 1.40 9.5 33 HI-E,minor; HI-P,monor; HI-N,major
3 33 F RA/RCMD INT-1 1.24 8.3 55 HI-E,major; HI-P,major; HI-N,major
6 73 F RARS/RCMDRS INT-1 1.30 8.2 102 HI-N,major
9 75 F RA/RCMD INT-1 0.65 5.3 21 HI-N,major
11 62 M RA/RA LOW 1.22 5.8 114 HI-E,major; HI-N,major
12 60 M RA/RA INT-1 0.89 11.4 14 HI-P,major
13 55 F RAEB/RAEB-II HIGH 0.38 9.5 88 HI-P,major
15 72 F RARS/RARS INT-1 2.25 8.0 152 HI-E,minor
18 62 F RA/RA INT-1 0.86 8.0 86 HI-E,minor; HI-P,minor; HI-N,major
19 58 F RA/RCMD INT-1 0.70 7.0 20 HI-E,major
Table 3. The clinical and laboratory characteristics and the hematologic response in the responding patients (n=11)
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Fig. 1. Graphic presentation of the hemoglobin levels and RBC
requirements for the patients with a RBC response after PCD treat-
ment.
UPN 1
UPN 2
UPN 3
UPN 11
UPN 15
UPN 18
UPN 19Hematologic Response to Anti-apoptotic Cytokine Therapy 43
Drug tolerance and toxicities
Of the 23 patients who could be evaluated for drug toxic-
ities, 39% of the patients experienced some type of toxici-
ties, and 2 patients discontinued their therapy prematurely
because of their intolerable epigastric sores and nausea, respec-
tively. However there was no grade 3 or worse severe toxici-
ties, and the treatment was relatively well tolerated (Table 4).
Although we were concerned about infectious complications
due to the long term steroid therapy, there was no significant
incidence of infection. 
Comparison of the clinical characteristics of the responders
and non-responders
The platelet responders had a shorter disease duration (p=
0.03) and they had a tendency for higher pretreatment neu-
trophil, hemoglobin and platelet counts (p=0.19, 0.06 and
0.19 respectively). The RBC responders had a trend of a bet-
ter karyotype risk (p=0.17), and the neutrophil responders
had a tendency for a lower international prognostic scoring
system (IPSS) (p=0.25) (Table 5).
DISCUSSION
Since TNF- may be the proximal inhibitor of a variety of
proinflammatory cytokines, those treatment strategies that
have employed a number of therapeutic agents with anti-
TNF properties such as amifostine, pentoxyphylline-ciproflo-
xacin-dexamethasone, thalidomide, soluble tumor necrosis
factor- receptor and monoclonal anti-TNF antibody have
been conducted with varying degree of success (17-24). Based
on these previous results, we evaluated an experimental reg-
imen that consisted of modified doses of pentoxifylline (P),
ciprofloxacin (C) and dexamethasone (D) in an attempt to
improve the toxicity profile and to maintain the treatment
efficacy for myelodysplastic syndrome. The results of this
trial are summarized as follows: Of the 21 evaluable patients,
eleven patients (52%) showed an improvement of their cyto-
penia. 3 patients had a triple lineage response, 1 patient had
a dual lineage response, and 7 patients had a single lineage
response. No differences were noted for the response rates
among the 3 lineages. There were no differences in the response
rates between the FAB subtypes, but the responders had a
shorter disease duration and a tendency for higher pretreat-
ment neutrophil, hemoglobin and platelet counts, a better
karyotype risk and a lower IPSS. These findings are similar
to the results of the other anti-cytokine therapies (17, 23).
The mechanism of the treatment response is thought to
involve the suppression of the proinflammatory cytokines
such as TNF- , with the consequent suppression of apopto-
sis in the hematopoietic cells, and there is a resultant regres-
sion of the MDS clones and stimulation of hematopoiesis in
the normal cells (21). Yet in some studies that have used solu-
ble TNF- , the clinical response rate was low and there was
no correlation between the level of TNF- production and
any of the clinical parameters or features of MDS (22). This
result may suggest that the apoptotic pathways in MDS are
redundant and they are mediated by many cytokines with
overlapping specificities, or that the dosage, duration of therapy
and frequency of administration may not have been optimal.
More recently, one study has reported a 20-38% response
rate when using an anti-TNF monoclonal antibody, Remi-
cade (24). 
Meanwhile, in addition to the standard chemotherapeutic
NCI-CTC Grade: No. (%) of 
patients (n=23) Symptoms
Grade 1 Grade 2
Nausea 0 3 (13)
Anorexia 0 1 (4)
Hypertension 0 0
Cushingoid appearance NA 3 (13)
Hyperglycemia 3 (13) 0
Mood alteration 0 0
Epigastric sore 1 (4) 1 (4)
Table 4. Adverse effects of PCD therapy 
Fig. 2. Graphic presentation of the platelet levels for the patients
with a platelet response after PCD treatment.
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with a neutrophil response after PCD treatment.
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drugs, a variety of novel agents like decitabine, Mylotarg,
farnesyl transferase inhibitors and arsenic have been employed
in attempt to eliminate the MDS clones. While each strategy
has produced important clinical responses for some of the
patient subset, none of these strategies is of universal benefit
for all MDS patients (25-27). The nucleoside analogues 5-
azacytidine have activity both as a DNA methyltransferase
inhibitor and as a cytotoxic agent, and the patients treated
with this drug have shown a 60% response rate and a sur-
vival benefit over the best supportive care for patients with
MDS (28). 
There are several limitations to our study. First of all, the
use of multiple agents precluded a precise dissection of the
mechanism of response, and another limitation was that the
TNF- concentrations were not measured. Thus, whether
the hematologic improvements we observed were a direct
result of the anti-TNF effect of the PCD therapy remains
uncertain. Still another limitation was that the clinical ben-
efit and the improvement of the quality of life after treatment
were not assessed.
Since the therapy was well tolerated, it is worthwhile to
consider a combination therapy with an agent that directly
affects the MDS cell clones such as topotecan, arsenic trioxide,
farnesyl-transferase inhibitor, 5-azacytidine or decitabine.
In conclusion, these preliminary results indicate that anti-
cytokine therapy with PCD is well tolerated for patients with
MDS. Although this approach may not prove to be wholly
curative in the long run, it provides substantial palliative
support for at least some of the MDS patients.
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